Akèy › Kansè poumon › Illinois › Joliet
Etid klinik pou Kansè poumon nan Joliet, IL
12 etid pou Kansè poumon ap chèche patisipan nan sit nan ak bò kote Joliet (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- UC Comprehensive Cancer Center at Silver Cross, New Lenox · 6 mi lwen
- University of Chicago Medicine-Orland Park, Orland Park · 14 mi lwen
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Ap rekriteFaz 3
- Northwestern Medicine Orland Park, Orland Park · 14 mi lwen
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- Northwestern Medicine Orland Park, Orland Park · 14 mi lwen
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Ap rekriteFaz 2
- Hope and Healing Clinical Research, New Lenox · 6 mi lwen
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Hope and Healing Cancer Services, New Lenox · 6 mi lwen
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Ap rekriteFaz 2
- Hope and Healing Clinical Research, New Lenox · 6 mi lwen
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Ap rekriteFaz 3
- Hope and Healing Cancer Services, New Lenox · 6 mi lwen
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Ap rekriteFaz 1/2
- UC Comprehensive Cancer Center at Silver Cross, New Lenox · 6 mi lwen
- University of Chicago Medicine-Orland Park, Orland Park · 14 mi lwen
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- University of Chicago, New Lenox · 6 mi lwen
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Northwestern Medicine Orland Park, Orland Park · 14 mi lwen
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Northwestern Medicine Orland Park, Orland Park · 14 mi lwen
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Northwestern Medicine Orland Park, Orland Park · 14 mi lwen
Etid Kansè poumon nan lòt vil
- Houston, TX78 etid
- Boston, MA62 etid
- New York City, NY60 etid
- Los Angeles, CA45 etid
- Washington, DC41 etid
- Arlington, VA41 etid
- Chicago, IL41 etid
- Nashville, TN40 etid
- Baltimore, MD40 etid
- St. Louis, MO39 etid
- Columbus, OH37 etid
- Philadelphia, PA36 etid
Lòt etid nan Joliet
- Kansè Poumon ki pa ti selil12 etid
- Kansè Metastatik7 etid
- Kansè vejik7 etid
- Karsinòm selil skuamèz tèt ak kou6 etid
- Kansè pwostat5 etid
- Kansè Ipofaringe5 etid
- Kansè larinks5 etid
- Kansè bouch5 etid
- Leksemi mieloïd egi5 etid
- Kansè nan tete4 etid
- Kansè kolon4 etid
- Kansè renn (Kasinom selil renn)4 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.